has been cited by the following article(s):
|
[1]
|
A systematic comparison of different composite measures (DAS 28, CDAI, SDAI, and Boolean approach) for determining treatment effects on low disease activity and remission in rheumatoid arthritis
BMC Rheumatology,
2022
DOI:10.1186/s41927-022-00314-7
|
|
|
|
|
[2]
|
Clinical significance of serum B cell chemokine (CXCL13) in early rheumatoid arthritis patients
The Egyptian Rheumatologist,
2018
DOI:10.1016/j.ejr.2018.04.003
|
|
|
|